{"id":"W4224252082","doi":"10.1016/j.eclinm.2022.101409","title":"Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)","year":2022,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"Biomedical Advanced Research and Development Authority; Genentech; H. Lundbeck A/S; Swedish Orphan Biovitrum; Novo Nordisk; Lundbeckfonden; Gilead Sciences; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; Erik og Susanna Olesens Almenvelgørende Fond; LivaNova; Pfizer; Bristol-Myers Squibb; AstraZeneca; Bayer HealthCare; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Tocilizumab; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Pneumonia; Betacoronavirus; Antibody; Virology; Viral pneumonia; Intensive care medicine; Internal medicine; Immunology; Outbreak; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007731777,0.0004991997,0.003097725,0.0004098439,0.0004362669,0.00002497394,0.0003937589,0.0001991269,0.0008489505],"category_scores_gemma":[0.1899336,0.0003540121,0.0004051243,0.0007558719,0.0009780523,0.00009642552,0.0006431606,0.001754882,0.00001745956],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006595138,"about_ca_system_score_gemma":0.001741285,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005153355,"about_ca_topic_score_gemma":0.00003554242,"domain_scores_codex":[0.9910679,0.002479237,0.002297329,0.001289016,0.002067665,0.0007988265],"domain_scores_gemma":[0.9262281,0.07053363,0.0006439183,0.001105874,0.0002501728,0.001238287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9195718,0.003167103,0.07338438,0.00007496407,0.0004959854,0.0006189297,0.0004927222,0.00008504204,0.0001408039,0.00001104559,0.0006599328,0.001297348],"study_design_scores_gemma":[0.626343,0.02131536,0.3452588,0.0001146908,0.0002908044,0.000001720935,0.0001077999,0.000452732,0.000001326279,0.0001005358,0.005779973,0.0002332884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9468316,0.0003111029,0.0000968908,0.04019264,0.0004338209,0.01168873,0.0001272115,0.0001294897,0.0001885291],"genre_scores_gemma":[0.9865347,0.0004287252,0.0001114279,0.01081334,0.0004061344,0.0009438876,0.0002060541,0.00006596312,0.0004897459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2932287,"threshold_uncertainty_score":0.9998912,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02606144175745058,"score_gpt":0.3980368495102848,"score_spread":0.3719754077528343,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}